Hospitais da Universidade de Coimbra-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2023

  1. Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies

    Autism Research, Vol. 16, Núm. 10, pp. 2021-2034

2021

  1. Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)

    Journal of Autism and Developmental Disorders, Vol. 51, Núm. 8, pp. 2959-2972

  2. Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) (Journal of Autism and Developmental Disorders, (2021), 51, 8, (2959-2972), 10.1007/s10803-020-04709-8)

    Journal of Autism and Developmental Disorders

2020

  1. Nocturnal enuresis: A proposal to optimize its management

    Acta Pediatrica Espanola, Vol. 78, Núm. 3-4, pp. 33-38

2016

  1. Secondary coenzyme Q10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders

    Mitochondrion, Vol. 30, pp. 51-58

2013

  1. Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: Round robin test

    Archives of Pathology and Laboratory Medicine, Vol. 137, Núm. 9, pp. 1255-1261